Prognostic value of immunohistochemistry in the Ewing's sarcoma family of tumors

Medical Science Monitor

Volumn 15, Issue 8, 2009, Pages

  Kavalar, Rajko ^a   Marinšek, Živa Pohar ^b   Jereb, Berta ^b   Čagran, Branka ^c   Golouh, Rastko ^b  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c UNIVERSITY OF MARIBOR   (Slovenia)

Author keywords

Ewing's sarcoma family of tumors; Immunohistochemistry; Prognostic factors; Survival analysis; Tissue array method

Indexed keywords

CD99 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DNA NUCLEOTIDYLEXOTRANSFERASE; DOXORUBICIN; EPIRUBICIN; EPITHELIAL MEMBRANE ANTIGEN; ETOPOSIDE; IFOSFAMIDE; MONOCLONAL ANTIBODY; NEURON SPECIFIC ENOLASE; PROTEIN BCL 2; PROTEIN P53; PROTEIN S 100; STEM CELL FACTOR; VINCRISTINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EWING SARCOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR NECROSIS;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; SARCOMA, EWING'S; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 68549107783     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Paulussen M, Ahrens S, Dunst AJ et al: Localised Ewing tumor of bone: final results of the cooperative Ewing's sarcoma study CESS 86. J Clin Oncol, 2001; 19: 1818-1829 (Pubitemid 32230885)
2. Folpe AL, Hill CE, Parham DM et al: Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol, 2000; 24: 1657-1662
3. Llombart-Bosch A, Navarro S: Immunohistochemical detection of EWS and FLI-1 proteins in Ewing sarcoma and primitive neuroectodermal tumors: comparative analysis with CD99 (MIC-2) expression. App Immunohistochem Mol Morphol, 2001; 9: 255-260 (Pubitemid 32783049)
4. Harms D: Soft tissue sarcoma in the Kiel pediatric registry. Curr Top Pathol, 1995; 89: 39-41
5. Stocker JT, Dehner LP: Pediatric Pathology (Second Edition). Philadelphia, Lippincot Williams&Wilkins, 2001
6. Parham DM, Hijazi Y, Steinberg SM et al: Neuroectodermal differentiation in Ewing's sarcoma family of tumors does not predict tumor behavior. Hum Pathol, 1999; 30: 911-918 (Pubitemid 29380514)
7. Athale UH, Shurtleff SA, Jenkins JJ et al: Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma. Ewing sarcoma family of tumors, and desmoplastic small round cell tumor. J Pediatr Hematol Oncol, 2001; 23:99-104
8. Folpe Al, Chand EM, Goldblum JR, Weiss SW: Expression of fli-1, a nuclear transcripting factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol, 2001; 25:1061-1066
9. Burchill SA: Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. J Clin Pathol, 2003; 56: 96-102 (Pubitemid 36177250)
10. Schleiermacher G, Peter M, Oberlin O et al: Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol, 2003; 21: 85-91
11. Koscielniak E, Morgan M, Treuner J: Soft tissue sarcoma in children: prognosis and management. Pediatr Drugs, 2002; 4: 21-28 (Pubitemid 34208343)
12. De Alava E, Antonescu CR, Panizo A et al: Prognostic impact of p53 status in Ewing sarcoma. Cancer, 2000; 89: 783-792 (Pubitemid 30658577)
13. Dunst J, Ahrens S, Paulussen M et al: Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. Int J Radiat Oncol Biol Phys, 1998; 42: 379-384 (Pubitemid 28502786)
14. Marinšek ŽP, Kavalar R, Jereb B: Ewing sarcoma/PNET: 27 years of experience in Slovenia. Pediatr Hematol Oncol, 2006; 23(4): 355-367
15. Abudu A, Mangham DC, Reynolds GM et al: Over-expression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer, 1999; 79: 1185-1189 (Pubitemid 29087896)
16. Toretsky JA, Steinberg SM, Thakar M et al: Insulin-like growth factor type 1(IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer, 2001; 92: 2941-2947 (Pubitemid 33091932)
17. Tsokos M, Steinberg SM, Stocker DM et al: Bcl2 may be predictive of survival in patients with peripheral primitive neuroectodermal tumors (PNET). Mod Pathol, 1995; 8: 145A
18. Perri T, Fogel M, Mor S et al: Effect of P-glycoprotein expression on outcome in the Ewing family of tumors. Pediatr Hematol Oncol, 2001; 18: 325-340 (Pubitemid 32625513)
19. Scotlandi K, Manara MC, Hattinger CM et al: Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer, 2005; 41(9): 1349-1361 (Pubitemid 40813013)
20. Ahmed A, Gilbert-Barness E, Lascon A: Expression of c-kit in Ewing family of tumors; a comparison of different immunohistochemical protocols. Pediatr Dev Pathol, 2004; 7: 342-347 (Pubitemid 39145705)
21. Fellinger EJ, Garin-Chesa P, Triche TJ et al: Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32 MIC2. Am J Pathol, 1991; 139: 317-325
22. Devoe K, Weidner N: Immunohistochemistry of small round-cell tumors. Semin Diagn Pathol, 2000; 17: 216-224
23. Weidner N, Tjoe J: Immunohistochemical profile of monoclonal antibody 013: antibody that recognized glycoprotein p30/32 MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma. Am J Surg Pathol, 1994; 18: 486-494 (Pubitemid 24134090)
24. Scotlandi K, Manara MC, Strammiello R et al: C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol, 2003; 21: 1952-1960 (Pubitemid 46606383)
25. Galli SJ, Zsebo KM, Geissler EN: The kit ligand stem cell factor. Adv Immunol, 1994; 55: 1-96 (Pubitemid 2026071)
26. Hirota S, Nishida T, Isozaki K et al: Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumors. J Pathol, 2001; 193: 505-510 (Pubitemid 32266820)
27. Landuzzi L, De Giovanni C, Nicoletti G et al: The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. Am J Pathol, 2000; 157: 2123-2131
28. Miettinen M, Sobin LH, Sarlomo-Rikala M: Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol, 2000; 13: 1134-1142
29. Miettinen M, Sarlomo-Rikala M, Lasota J: KIT expression in angiosarcomas and fetal cells: lack of mutations of exon 11 and exon 17 of C-kit. Mod Pathol, 2000; 13: 536-541 (Pubitemid 30332105)
30. Hibi K, Takahashi T, Sekido Y et al: Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene, 1991; 6: 2291-2296 (Pubitemid 21924076)
31. Beghini A, Peterlongo P, Ripamonti CB et al: C-kit mutations in core binding factor leukemias. Blood, 2000; 95: 726-727 (Pubitemid 30041697)
32. Kitamura Y, Hirota S, Nishida T: A loss-of-function mutation of c-kit results in depletion of mast cells and interstitial cells of Cajal, while its gain-of-function mutation results in their oncogenesis. Mutat Res, 2001; 477: 165-171 (Pubitemid 32480199)
33. Lai R, Arber DA, Chang KL et al: Frequency of bcl-2 expression in non-Hodgkin's lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia. Modern Pathology, 1998; 11: 864-869 (Pubitemid 28440883)
34. Lane DP: A death in the life of p53. Nature, 1993; 362: 786-787
35. Ghule P, Kadam PA, Jambhekar N et al: p53 gene gets altered by various mechanisms: studies in childhood sarcomas and retinoblastoma. Med Sci Monit, 2006; 12(12): 385-396 (Pubitemid 44916054)
36. Mangham DC, Cannon A, Li XQ et al: p53 overexpression in Ewing's sarcoma /primitive neuroectodermal tumours is an uncommon event. J Clin Mol Pathol, 1995; 48: M79-M82
37. Schmechel D: Editorial. Gamma-Subunit of the glycolic enzyme enolase: Nonspecific or neuron specific? Lab Invest, 1985; 52: 239-242
38. Willander E, Pahlman S, Sallstrom J, Lindgren A: Neuron-specificenolase expression and neuroendocrine differentiation in carcinomas of the breast. Arch Pathol Lab Med, 1987; 111: 830-832 (Pubitemid 17121988)
39. Erikstein B, Nesland JM, Ottestad L et al: Neuron specific enolase-positive breast carcinomas. Histol Histopath, 1988; 3: 97-102 (Pubitemid 18127311)
40. Bollum FJ: Review: Terminal deoxynucleotidyl transferase as a hematopoietic cell marker. Blood, 1979; 54(6):1203
41. Cordell J, Richardson TC, Pulford KAF et al: Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry. Br J Cancer, 1985; 52: 347-354 (Pubitemid 16217875)
42. Pinkus GS, Etheridge CL, O'Connor EM: Are keratin proteins a better tumor marker than epithelial membrane antigen? Am J Clin Pathol, 1986; 85: 269-277
43. Delsol G, Al Saati T, Gatter KC et al: Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Am J Pathol, 1988; 130: 59-70
44. Nakamura Y, Becker LE, Marks A: S-100 protein in tumors of cartilage and bone. An immunohistochemical study. Cancer, 1983; 52:1820-1824
45. Kindblom L-G, Lodding P, Rosengren L et al: S-100 protein in melanocytic tumors. Acta path microbiol immunol scand Sect A, 1984; 92: 219-230
46. Wick MR, Swanson PE, Rocamora A: Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors. J Cutan Pathol, 1988; 15: 201-207
47. Ramaekers FCS, Pruszczynski M, Smedts F: Cytokeratins in smooth muscle cells and smooth muscle tumours. Histopathology, 1988; 12: 558-561 (Pubitemid 18186305)
48. Goddard MJ, Wilson B, Grant JW: Comparison of commercially available cytokeratin antibodies in normal and neoplastic adult epithelial and non-epithelial tissues. J Clin Pathol, 1991; 44: 660-663
49. Rosen G, Caparros B, Nirenberg A et al: Ewing's sarcoma: Ten-year experience with adjuvant chemotherapy. Cancer, 1981; 47: 2204-2213 (Pubitemid 11098590)
50. Packeisen J, Buerger H, Krech R, Boecker W: Tissue microarrays: a new approach for quality control in immunohistochemistry. J Clin Pathol, 2002; 55: 613-615 (Pubitemid 34888306)
51. Cox DR, Oakes D: Analysis of survival data. Chapman & Hall, New York, 1984
52. Vogt WP: Dictionary of Statistics & Methodology. Thousand Oaks, CA: Sage Publications, 2005
53. Hornick JL, Fletcher CDM: Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol, 2002; 117: 188-193
54. Amir G, Issakov J, Meller I et al: Expression of p53 gene product and cell proliferation marker Ki-67 in Ewing's sarcoma: Correlation with clinical outcome. Hum Pathol, 2002; 33(2): 170-174 (Pubitemid 34298731)
55. Vakar-López F, Ayala AG, Raymond AK, Czerniak B: Epithelial Phenotype in Ewing's Sarcoma/Primitive Neuroectodermal Tumor. Int J Surg Pathol, 2000; 8(1):59-65 (Pubitemid 30129569)
56. Lucas DR, Bentley G, Dan ME et al: Ewing sarcoma vs lymphoblastic lymphoma. A comparative immunohistochemical study. Am J Clin Pathol, 2001; 115(6): 933-934
57. Ehrig T, Billings SD, Fanburg-Smith JC: Superficial primitive neuroectodermal tumor/Ewing sarcoma (PN/ES): same tumor as deep PN/ES or new entity? Ann Diagn Pathol, 2007; 11: 153-159
58. Toda T, Atari E, Sadi AM et al: Primitive neuroectodermal tumor in sinonasal region. Auris Nasus Laryngs, 1999; 26: 83-90 (Pubitemid 29042434)
59. Coffin CM, Dehner LP: Neurogenic tumors of soft tissue. In: Coffin CM, Dehner LP, O'Shea PA: Pediatric Soft Tissue Tumors: A Clinical, Pathological, and Therapeutic Approach. Baltimore, MD: Williams and Wilkins, 1997; 80-132
60. Riley RD, Burchill SA, Abrams KR et al: A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family. Eur J Cancer, 2003; 39: 19-30 (Pubitemid 36005421)
61. Amann G, Zoubek A, Salzer-Kuntschnik M et al: Relation of neurological marker expression and EWS gene fusion types in MIC2/CD99-positive tumors of the Ewing family. Hum Pathol, 1999; 30: 1058-1064 (Pubitemid 29427162)
62. Antunes NL, Lellouch-Tubiana A, Kalifa C et al: Intracranial Ewing sarcoma/«peripheral« primitive neuroectodermal tumor of dural origin with molecular genetic confirmation. J Neurooncol, 2001; 51: 51-56
63. Llombart-Bosch A, Contesso G, Henry-Amar M et al: Histopathological predictive factors in Ewing's sarcoma of bone and clinicopathological correlations. Virchows Arch, 1986; 409: 627-640
64. Cotterill SJ, Ahrens S, Paulussen M et al: Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European intergroup cooperative Ewing's sarcoma study group. J Clin Oncol, 2000; 18: 3108-3114 (Pubitemid 30677091)